JP2024507118A - 抗トランスフェリン受容体融合タンパク質及びその使用方法 - Google Patents

抗トランスフェリン受容体融合タンパク質及びその使用方法 Download PDF

Info

Publication number
JP2024507118A
JP2024507118A JP2023547794A JP2023547794A JP2024507118A JP 2024507118 A JP2024507118 A JP 2024507118A JP 2023547794 A JP2023547794 A JP 2023547794A JP 2023547794 A JP2023547794 A JP 2023547794A JP 2024507118 A JP2024507118 A JP 2024507118A
Authority
JP
Japan
Prior art keywords
seq
fusion protein
amino acid
acid sequence
mol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547794A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022174114A5 (https=
JP2024507118A5 (https=
Inventor
アニー アルゲロ，
ティナ ジース，
グナセカラン カナン，
ミハリス エス． カリオリス，
カタル エス． マホーン，
ジュンファ ワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2024507118A publication Critical patent/JP2024507118A/ja
Publication of JPWO2022174114A5 publication Critical patent/JPWO2022174114A5/ja
Publication of JP2024507118A5 publication Critical patent/JP2024507118A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023547794A 2021-02-11 2022-02-11 抗トランスフェリン受容体融合タンパク質及びその使用方法 Pending JP2024507118A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148543P 2021-02-11 2021-02-11
US63/148,543 2021-02-11
PCT/US2022/016229 WO2022174114A1 (en) 2021-02-11 2022-02-11 Anti-transferrin receptor fusion proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024507118A true JP2024507118A (ja) 2024-02-16
JPWO2022174114A5 JPWO2022174114A5 (https=) 2025-02-18
JP2024507118A5 JP2024507118A5 (https=) 2025-02-18

Family

ID=82837358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547794A Pending JP2024507118A (ja) 2021-02-11 2022-02-11 抗トランスフェリン受容体融合タンパク質及びその使用方法

Country Status (6)

Country Link
US (3) US20240148866A1 (https=)
EP (1) EP4291246A4 (https=)
JP (1) JP2024507118A (https=)
CN (1) CN116997364A (https=)
MA (1) MA71665A (https=)
WO (1) WO2022174114A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260015409A1 (en) * 2022-09-20 2026-01-15 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of membrane proteins and cargos
AR131281A1 (es) 2022-12-05 2025-03-05 Sanofi Sa Proteínas de unión al receptor de transferrina
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018038243A1 (ja) * 2016-08-25 2018-03-01 Ｊｃｒファーマ株式会社 抗体融合蛋白質の製造方法
US20180171012A1 (en) * 2015-06-24 2018-06-21 Jcr Pharmaceuticals Co., Ltd. Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier
US20190336586A1 (en) * 2016-12-28 2019-11-07 Jcr Pharmaceuticals Co., Ltd. Lyophilized Preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032913A2 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
BR112014000352A2 (pt) * 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
US9994641B2 (en) * 2013-12-25 2018-06-12 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody that passes through blood-brain barrier
TWI761413B (zh) * 2016-12-26 2022-04-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
AU2018345303B2 (en) * 2017-10-02 2025-09-18 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
JP7458404B2 (ja) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド イズロン酸－２－スルファターゼ免疫グロブリン融合タンパク質の精製

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180171012A1 (en) * 2015-06-24 2018-06-21 Jcr Pharmaceuticals Co., Ltd. Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier
WO2018038243A1 (ja) * 2016-08-25 2018-03-01 Ｊｃｒファーマ株式会社 抗体融合蛋白質の製造方法
US20190336586A1 (en) * 2016-12-28 2019-11-07 Jcr Pharmaceuticals Co., Ltd. Lyophilized Preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OKUYAMA, T. ET AL.: "A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targe", MOLECULAR THERAPY, vol. 29, no. 2, JPN6026012822, 3 February 2021 (2021-02-03), pages 671 - 679, ISSN: 0005831049 *
SAFARY, A. ET AL.: "Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolys", CELLULAR AND MOLECULAR LIFE SCIENCES, vol. 76, no. 17, JPN6026012820, 2019, pages 3363 - 3381, ISSN: 0005831051 *
SONODA, H. ET AL.: "A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuron", MOLECULAR THERAPY, vol. 26, no. 5, JPN6026012821, 2018, pages 1366 - 1374, ISSN: 0005831050 *

Also Published As

Publication number Publication date
EP4291246A4 (en) 2024-12-11
CN116997364A (zh) 2023-11-03
US20250367284A1 (en) 2025-12-04
EP4291246A1 (en) 2023-12-20
WO2022174114A1 (en) 2022-08-18
MA71665A (fr) 2025-05-30
US20250387477A1 (en) 2025-12-25
US20240148866A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
EP2844289B1 (en) Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CN103649114B (zh) 新的免疫缀合物
JP2023123757A (ja) トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
US20250367284A1 (en) Anti-transferrin receptor fusion proteins and methods of use thereof
CN107250158A (zh) 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
TW201731875A (zh) 人類化抗人類cd19抗體及使用方法
KR20210074279A (ko) 항-her2 폴리펩타이드 및 이의 사용방법
CN115916830A (zh) 抗cd3/抗cd28双特异性抗原结合分子
CN110352202A (zh) 抗pd-l1抗体和il-7融合蛋白
TW202003570A (zh) 抗trem-1抗體及其用途
CN116075525A (zh) 抗mertk抗体及其使用方法
WO2019235426A1 (ja) 細胞質内での半減期が変化した抗原結合分子
JP2023545707A (ja) スルホグルコサミンスルホヒドロラーゼ酵素を含む融合タンパク質及びその方法
KR20220156526A (ko) 조작된 항-her2 이중특이성 단백질
TW202342519A (zh) 人源化抗ｔｄｐ－４３結合分子及其用途
US20220112258A1 (en) Bifunctional molecules with il-7 activity
WO2023192282A1 (en) Methods for treating brain glucose hypometabolism
WO2024206161A1 (en) Abeta-targeting proteins and methods of use
TW202340459A (zh) 包含α—Ｌ—艾杜糖醛酸酶之融合蛋白及其方法
CN117715933A (zh) 抗vista的构建体及其用途
JP7089483B2 (ja) 修飾された抗テネイシン抗体及び使用方法
JP2024544924A (ja) トランスサイレチン（ｔｔｒ）単量体結合抗体
TW202515915A (zh) 抗ｐｉｌｒａ抗體、其用途以及相關方法及試劑
KR20240052019A (ko) 항-her2 항체 및 이의 사용 방법
HK40108627A (zh) 抗vista的构建体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260401